Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

- Presentations to Highlight CLS-AX as Promising Wet AMD Treatment with New Mechanism of Action and Potential for Longer Duration of Effect than Current Therapies -

ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that presentations will be delivered at the American Society of Retina Specialists (ASRS) 41^st Annual Scientific Meeting and the Ophthalmology Innovation Source (OIS) Retina Innovation Summit taking place July 27 – August 1, 2023 in Seattle, WA.

Ophthalmology Innovation Source (OIS) Retina Innovation Summit
Session: Spotlight on Drug Delivery
Moderator: Thomas A. Ciulla, M.D., MBA, Chief Medical Advisor-Retina and Chair, Scientific Advisory Board
Presenter: George Lasezkay, Pharm.D., J.D., President & Chief Executive Officer
Date: Thursday, July 27, 2023
Time: 10:50 – 11:50 am PT

American Society of Retina Specialists (ASRS)
Session: Wet AMD Symposium 2
Title: Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Presenter: Rahul N. Khurana, MD, FASRS
Date: Sunday, July 30, 2023
Time: 8:37 am PT

About CLS-AX (axitinib injectable suspension)

CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in preclinical studies in multiple species and in a Phase 1/2a wet AMD clinical trial in which CLS-AX was well tolerated and demonstrated an excellent safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers while limiting drug exposure to the front of the eye. Clearside is developing CLS-AX as a long-acting therapy for the treatment of retinal diseases.